Valuation: Winston Pharmaceuticals, Inc.

Market Cap	15.48M 13.26M 12.41M 11.36M 21.32M 1.48B 21.6M 147M 57.17M 744M 58.13M 56.87M 2.46B	P/E 2008	-49.9x	P/E 2009	-6.46x
Enterprise Value	13.92M 11.92M 11.16M 10.21M 19.17M 1.33B 19.42M 132M 51.4M 669M 52.26M 51.13M 2.21B	EV / Sales 2008	572x	EV / Sales 2009	14.4x
Free-Float	100%	Yield 2008 *	-	Yield 2009	-

* Estimated data More valuation ratios

Latest news : Winston Pharmaceuticals, Inc.

12-04-09

Winston Pharmaceuticals, Inc. Receives SBIR Grant from the NIH to Investigate Treatment for Postherpetic Neuralgia of the Trigeminal Nerve

More news

Managers and Directors: Winston Pharmaceuticals, Inc.

Manager	Title	Age	Since
Joel E. Bernstein CEO	Chief Executive Officer	83	2010-02-18

More insiders

Winston Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company discovers, develops and commercializes therapeutics for managing and alleviating pain. The Company's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The Company is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The Company's other products are under development for the treatment of headache and neuropathic and rheumatological pain.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 14:34:44 2026-04-29 EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.3
10 years	0		0.3

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WINSTON PHARMACEUTICALS, INC.	-99.00%	-.--%	-	-	77
ELI LILLY AND COMPANY	+0.88%	+6.38%	+76.40%	+126.75%	1,119B
JOHNSON & JOHNSON	+1.07%	+3.80%	+50.73%	+62.78%	651B
ABBVIE INC.	+1.20%	+6.21%	+25.81%	+78.74%	468B
ROCHE HOLDING AG	+1.02%	+5.77%	+43.63%	+48.43%	374B
NOVARTIS AG	+0.85%	+4.07%	+24.97%	+40.58%	302B
ASTRAZENECA PLC	+1.26%	+6.81%	+2.27%	+14.41%	259B
AMGEN INC.	+1.88%	+5.81%	+49.57%	+70.53%	238B
NOVO NORDISK A/S	+1.59%	+2.09%	-17.33%	-52.62%	208B
GILEAD SCIENCES, INC.	+1.87%	+5.61%	+27.32%	+91.38%	181B
Average	-8.74%	+4.48%	+31.49%	+53.44%	379.99B
Weighted average by Cap.	+1.14%	+5.09%	+44.26%	+72.65%

	2008	2009
Net sales	453K 388K 363K 332K 623K 43.3M 631K 4.29M 1.67M 21.75M 1.7M 1.66M 71.94M	1.39M 1.19M 1.12M 1.02M 1.92M 133M 1.95M 13.21M 5.15M 67.03M 5.24M 5.12M 222M
Net income	-5.14M -4.4M -4.12M -3.77M -7.08M -492M -7.17M -48.69M -18.99M -247M -19.31M -18.89M -817M	-2.66M -2.27M -2.13M -1.95M -3.66M -254M -3.7M -25.14M -9.81M -128M -9.97M -9.75M -422M
Net Debt	-5.63M -4.82M -4.51M -4.13M -7.75M -538M -7.85M -53.28M -20.78M -270M -21.13M -20.67M -895M	-1.56M -1.34M -1.25M -1.15M -2.15M -150M -2.18M -14.8M -5.77M -75.12M -5.87M -5.74M -248M

Winston Pharmaceuticals, Inc. Stock

Stocks

WPHM

US9756571074

Pharmaceuticals

Valuation: Winston Pharmaceuticals, Inc.

Latest news : Winston Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Winston Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile